Based on the key indicators related to Roivant Sciences' liquidity, profitability, solvency, and operating efficiency, Roivant Sciences is doing better financially today then in previous quarter. It has a moderate odds of reporting better financial numbers in December. At this time, Roivant Sciences' Net Receivables is fairly stable compared to the past year. Liabilities And Stockholders Equity is likely to climb to about 7.6 B in 2024, whereas Other Current Liabilities is likely to drop slightly above 166.2 M in 2024. Key indicators impacting Roivant Sciences' financial strength include:
The essential information of the day-to-day investment outlook for Roivant Sciences includes many different criteria found on its balance sheet. An individual investor should monitor Roivant Sciences' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Roivant Sciences.
Net Income
4.57 Billion
Roivant
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Sale Purchase Of Stock
Investments
Change In Cash
Net Borrowings
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Other Cashflows From Investing Activities
Change To Netincome
Change To Liabilities
Issuance Of Capital Stock
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Other Liab
Net Tangible Assets
Property Plant And Equipment Net
Current Deferred Revenue
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Other Assets
Cash And Short Term Investments
Net Receivables
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Total Current Assets
Accumulated Other Comprehensive Income
Short Term Debt
Property Plant Equipment
Long Term Debt
Short Term Investments
Capital Lease Obligations
Inventory
Net Invested Capital
Long Term Investments
Property Plant And Equipment Gross
Non Current Liabilities Other
Net Working Capital
Discontinued Operations
Depreciation And Amortization
Interest Expense
Selling General Administrative
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Minority Interest
Tax Provision
Net Interest Income
Interest Income
Net Income From Continuing Ops
Probability Of Bankruptcy
Understanding current and past Roivant Sciences Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Roivant Sciences' financial statements are interrelated, with each one affecting the others. For example, an increase in Roivant Sciences' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Roivant Sciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Roivant Sciences. Check Roivant Sciences' Beneish M Score to see the likelihood of Roivant Sciences' management manipulating its earnings.
Roivant Sciences Stock Summary
Roivant Sciences competes with Eliem Therapeutics, HCW Biologics, Scpharmaceuticals, Milestone Pharmaceuticals, and Seres Therapeutics. Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company was founded in 2014 and is based in London, the United Kingdom. Roivant Sciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 863 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what Roivant Sciences' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Roivant Sciences's current stock value. Our valuation model uses many indicators to compare Roivant Sciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Roivant Sciences competition to find correlations between indicators driving Roivant Sciences's intrinsic value. More Info.
Roivant Sciences is currently regarded as top stock in return on equity category among its peers. It is rated second in return on asset category among its peers . At this time, Roivant Sciences' Return On Equity is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Roivant Sciences by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Roivant Sciences Systematic Risk
Roivant Sciences' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Roivant Sciences volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on Roivant Sciences correlated with the market. If Beta is less than 0 Roivant Sciences generally moves in the opposite direction as compared to the market. If Roivant Sciences Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Roivant Sciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Roivant Sciences is generally in the same direction as the market. If Beta > 1 Roivant Sciences moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Roivant Sciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Roivant Sciences' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Roivant Sciences growth as a starting point in their analysis.
Roivant Sciences November 25, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Roivant Sciences help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Roivant Sciences. We use our internally-developed statistical techniques to arrive at the intrinsic value of Roivant Sciences based on widely used predictive technical indicators. In general, we focus on analyzing Roivant Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Roivant Sciences's daily price indicators and compare them against related drivers.
When running Roivant Sciences' price analysis, check to measure Roivant Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roivant Sciences is operating at the current time. Most of Roivant Sciences' value examination focuses on studying past and present price action to predict the probability of Roivant Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roivant Sciences' price. Additionally, you may evaluate how the addition of Roivant Sciences to your portfolios can decrease your overall portfolio volatility.